Illumina (ILMN - Free Report) closed at $337.50 in the latest trading session, marking a -0.14% move from the prior day. This change lagged the S&P 500's daily gain of 0.82%. At the same time, the Dow added 0.79%, and the tech-heavy Nasdaq gained 0.79%.
Prior to today's trading, shares of the genetic testing tools company had gained 8.06% over the past month. This has outpaced the Medical sector's gain of 5.35% and the S&P 500's gain of 3.94% in that time.
Investors will be hoping for strength from ILMN as it approaches its next earnings release, which is expected to be January 29, 2019. In that report, analysts expect ILMN to post earnings of $1.35 per share. This would mark a year-over-year decline of 6.25%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $860.57 million, up 10.61% from the year-ago period.
ILMN's full-year Zacks Consensus Estimates are calling for earnings of $5.75 per share and revenue of $3.33 billion. These results would represent year-over-year changes of +43.75% and +20.98%, respectively.
Investors should also note any recent changes to analyst estimates for ILMN. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. ILMN is currently sporting a Zacks Rank of #2 (Buy).
Digging into valuation, ILMN currently has a Forward P/E ratio of 58.76. This valuation marks a premium compared to its industry's average Forward P/E of 25.18.
Also, we should mention that ILMN has a PEG ratio of 2.51. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.64 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 76, which puts it in the top 30% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
You can find more information on all of these metrics, and much more, on Zacks.com.